

## **EXHIBIT 5**

Selected information by business segment is as follows:

	Fiscal Year Ended			Three Months Ended
	December 29, 2017	September 30, 2016	September 25, 2015	December 30, 2016
<b>Net sales:</b>				
Specialty Brands	\$ 2,325.3	\$ 2,300.6	\$ 1,622.8	\$ 603.1
Specialty Generics	839.5	1,025.2	1,251.6	212.9
Net sales of operating segments <sup>(1)</sup>	3,164.8	3,325.8	2,874.4	816.0
Other <sup>(2)</sup>	56.8	55.0	48.7	13.9
Net sales	\$ 3,221.6	\$ 3,380.8	\$ 2,923.1	\$ 829.9
<b>Operating income:</b>				
Specialty Brands	\$ 1,155.2	\$ 1,166.2	\$ 637.6	\$ 317.2
Specialty Generics	231.5	376.1	594.4	52.7
Segment operating income	1,386.7	1,542.3	1,232.0	369.9
<b>Unallocated amounts:</b>				
Corporate and allocated expenses <sup>(3)</sup>	(172.0)	(169.8)	(282.6)	(181.4)
Intangible asset amortization	(694.5)	(700.1)	(550.3)	(175.7)
Restructuring and related charges, net <sup>(4)</sup>	(36.4)	(38.2)	(45.3)	(5.3)
Non-restructuring impairments	(63.7)	(16.9)	—	(214.3)
Operating income	\$ 420.1	\$ 617.3	\$ 353.8	\$ (206.8)
<b>Depreciation and amortization <sup>(5)</sup>:</b>				
Specialty Brands	\$ 708.2	\$ 716.6	\$ 559.5	\$ 178.4
Specialty Generics	100.1	96.8	81.6	24.8
	\$ 808.3	\$ 813.4	\$ 641.1	\$ 203.2

- (1) Amounts represent sales to external customers. There were no intersegment sales.
- (2) Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
- (3) Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
- (4) Includes restructuring-related accelerated depreciation.
- (5) Depreciation for certain **shared facilities** is allocated based on occupancy percentage.

Net sales by product family within the Company's segments are as follows:

	Fiscal Year Ended			Three Months Ended
	December 29, 2017	September 30, 2016	September 25, 2015	December 30, 2016
H.P. Acthar Gel	\$ 1,195.1	\$ 1,160.4	\$ 1,037.3	\$ 325.4
Inomax	505.2	474.3	185.2	118.3
Ofirmev	302.5	284.3	263.0	72.5
Therakos	214.9	207.6	—	47.4
Hemostasis products	55.1	42.5	—	13.4
Other	52.5	131.5	137.3	26.1
<b>Specialty Brands</b>	<b>2,325.3</b>	<b>2,300.6</b>	<b>1,622.8</b>	<b>603.1</b>
Hydrocodone (API) and hydrocodone-containing tablets	85.3	146.5	167.2	23.2
Oxycodone (API) and oxycodone-containing tablets	78.8	126.2	154.6	24.3
Methylphenidate ER	71.7	103.5	136.5	22.0
Other controlled substances	409.6	468.1	572.2	104.9
Other	194.1	180.9	221.1	38.5
<b>Specialty Generics</b>	<b>839.5</b>	<b>1,025.2</b>	<b>1,251.6</b>	<b>212.9</b>
Other <sup>(1)</sup>	56.8	55.0	48.7	13.9
<b>Net sales</b>	<b>\$ 3,221.6</b>	<b>\$ 3,380.8</b>	<b>\$ 2,923.1</b>	<b>\$ 829.9</b>

- (1) Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDs business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

Selected information by geographic area excluding assets held for sale is as follows:

	Fiscal Year Ended			Three Months Ended
	December 29, 2017	September 30, 2016	September 25, 2015	December 30, 2016
Net sales <sup>(1)</sup> :				
U.S.	\$ 2,899.0	\$ 3,095.4	\$ 2,647.0	\$ 763.7
Europe, Middle East and Africa	242.3	211.8	159.0	52.8
Other	80.3	73.6	117.1	13.4
	<b>\$ 3,221.6</b>	<b>\$ 3,380.8</b>	<b>\$ 2,923.1</b>	<b>\$ 829.9</b>

	Fiscal Year Ended	
	December 29, 2017	December 30, 2016
Long-lived assets <sup>(2)</sup> :		
U.S.	\$ 788.5	\$ 759.1
Europe, Middle East and Africa <sup>(3)</sup>	127.0	82.9
Other	63.5	51.5
	<b>\$ 979.0</b>	<b>\$ 893.5</b>

- (1) Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
- (2) Long-lived assets are primarily composed of property, plant and equipment, net.
- (3) Includes long-lived assets located in Ireland of \$126.0 million and \$80.9 million as of December 29, 2017 and December 30, 2016, respectively.